WO2007022477A3 - Methods and compositions to generate and control the effector profile of t cells - Google Patents

Methods and compositions to generate and control the effector profile of t cells Download PDF

Info

Publication number
WO2007022477A3
WO2007022477A3 PCT/US2006/032512 US2006032512W WO2007022477A3 WO 2007022477 A3 WO2007022477 A3 WO 2007022477A3 US 2006032512 W US2006032512 W US 2006032512W WO 2007022477 A3 WO2007022477 A3 WO 2007022477A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
cells
generate
control
Prior art date
Application number
PCT/US2006/032512
Other languages
French (fr)
Other versions
WO2007022477A2 (en
Inventor
Lilin Wang
Dan Smith
Bill Phillips
Adrian Bot
Original Assignee
Multicell Immunotherapeutics I
Lilin Wang
Dan Smith
Bill Phillips
Adrian Bot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multicell Immunotherapeutics I, Lilin Wang, Dan Smith, Bill Phillips, Adrian Bot filed Critical Multicell Immunotherapeutics I
Priority to EP06801942A priority Critical patent/EP1937300A4/en
Publication of WO2007022477A2 publication Critical patent/WO2007022477A2/en
Publication of WO2007022477A3 publication Critical patent/WO2007022477A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to novel compositions and methods and their use in treating an autoimmune disorder or achieving tolerance to an antigen. More specifically, the present invention is directed to human immunoglobulin constructs for loading a delivered T cell epitope on to the surface of an antigen presenting cell for achieving tolerance to that delivered T cell epitope. The present invention may be applied to any T cell epitope mediated autoimmune disorder.
PCT/US2006/032512 2005-08-17 2006-08-17 Methods and compositions to generate and control the effector profile of t cells WO2007022477A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06801942A EP1937300A4 (en) 2005-08-17 2006-08-17 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70898005P 2005-08-17 2005-08-17
US60/708,980 2005-08-17

Publications (2)

Publication Number Publication Date
WO2007022477A2 WO2007022477A2 (en) 2007-02-22
WO2007022477A3 true WO2007022477A3 (en) 2007-08-30

Family

ID=37758473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/032512 WO2007022477A2 (en) 2005-08-17 2006-08-17 Methods and compositions to generate and control the effector profile of t cells

Country Status (2)

Country Link
EP (1) EP1937300A4 (en)
WO (1) WO2007022477A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2367561E (en) 2008-11-30 2015-10-23 Immusant Inc Compositions and methods for treatment of celiac disease
AU2014318889B2 (en) 2013-09-10 2020-02-20 Immusant, Inc. Dosage of a gluten peptide composition
EP3201354A1 (en) 2014-09-29 2017-08-09 Immusant Inc. Use of hla genetic status to assess or select treatment of celiac disease
JP2018508481A (en) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム Targeted partial peptide epitope complex having multiple T cell epitopes
GB2576914A (en) * 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052820A1 (en) * 1993-06-07 2004-03-18 Duke University Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
US20040234531A1 (en) * 2001-05-07 2004-11-25 Sofia Casares Chimeric human leukocyte antigen and epitope-bearing molecules having immunosuppressant activity
US20050044588A1 (en) * 1997-10-07 2005-02-24 Langridge William H.R. Methods and substances for preventing and treating autoimmune disease
US20050074449A1 (en) * 2000-07-28 2005-04-07 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0973933A1 (en) * 1997-02-13 2000-01-26 American National Red Cross Immunological tolerance to hiv epitopes
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052820A1 (en) * 1993-06-07 2004-03-18 Duke University Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
US20050044588A1 (en) * 1997-10-07 2005-02-24 Langridge William H.R. Methods and substances for preventing and treating autoimmune disease
US20050074449A1 (en) * 2000-07-28 2005-04-07 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
US20040234531A1 (en) * 2001-05-07 2004-11-25 Sofia Casares Chimeric human leukocyte antigen and epitope-bearing molecules having immunosuppressant activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORZA ET AL.: "The Goodpasture Autoantigen", J. BIOL. CHEM., vol. 275, no. 8, 25 February 2000 (2000-02-25), pages 6030 - 6037, XP002240533 *
FRASER ET AL.: "Pathogenesis of celiac disease: implications for treatment", WORLD J. GASTROENTEROL., vol. 7, no. 6, 2001, pages 772 - 776, XP008125373 *

Also Published As

Publication number Publication date
EP1937300A2 (en) 2008-07-02
EP1937300A4 (en) 2009-08-12
WO2007022477A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2018023100A3 (en) Anti-idiotypic antibodies against anti-cd19 antibodies
WO2009136286A3 (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2007098420A8 (en) Peptides that block the binding of igg to fcrn
WO2006053301A3 (en) Fc variants with altered binding to fcrn
EP1539819A4 (en) Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells
WO2012020006A3 (en) Anti-fap antibodies and methods of use
SG170793A1 (en) Anti-mn antibodies and methods of using same
AU2013205271B2 (en) Human CGRP receptor binding proteins
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
HK1109636A1 (en) Human antibodies and proteins
EP2937361A3 (en) Fc variants with altered binding to fcRn
WO2006066078A3 (en) Fcϝriib-specific antibodies and methods of use thereof
WO2007042573A3 (en) Compositions and methods for treating proliferative disorders
SG169327A1 (en) Compositions and methods of use for antibodies of dickkopf-1 and/or -4
WO2008133938A3 (en) Targeted integration into the ppp1r12c locus
WO2006118772A3 (en) Fcrn antibodies and uses thereof
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
EP2497496A3 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2008122551A3 (en) Anti-epcam antibody and uses thereof
WO2007022477A3 (en) Methods and compositions to generate and control the effector profile of t cells
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2006013087A8 (en) Human monoclonal antibodies against human il-4
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
WO2012018767A3 (en) Antibodies directed against il-17

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006801942

Country of ref document: EP